Driving CAR T-cell Therapy in New Directions
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and...
Author:
Neha J. Pancholi, PhD
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO,...
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its...